北京若生智能科技有限公司
Drug Database
AD

adalimumab (Anjiarun / SCT630 / SCT 630)

✓ Approved

Sinocelltech · TNF · 单克隆抗体

什么是 adalimumab？

adalimumab 是一种单克隆抗体，由Sinocelltech研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Subcutaneous Injection。

药物档案

商品名Anjiarun, SCT630, SCT 630
公司Sinocelltech
药物类别单克隆抗体, 抗体
分子靶点TNF
给药途径Injectable (Others), Subcutaneous Injection
状态Approved
来源： ClinicalTrials.gov, Sinocelltech

作用机制

分子靶点

adalimumab 作用于 1 个分子靶点：

TNFtumor necrosis factor (TNFA, TNF-alpha)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

adalimumab 针对 10 个适应症，涉及 4 个治疗领域。

治疗领域疾病/病症分期
Skin and subcutaneous tissue disordersPsoriasis✓ Approved
Musculoskeletal and connective tissue disordersAnkylosing spondylitisPhase I
Musculoskeletal and connective tissue disordersRheumatoid arthritisPhase I
Gastrointestinal disordersColitis ulcerativePreclinical
Gastrointestinal disordersCrohn's diseasePreclinical

注册免费账户还可查看另外 5 个适应症

免费注册查看全部适应症 →

相关研究文献

PubMedRevista espanola de enfermedades digestivas2026-10-26

Biosimilars in inflammatory bowel disease: from initial uncertainty to clinical normalization.

Argüelles-Arias Federico F, Zabana Yamile Y

Biosimilars have become an integral part of the treatment of inflammatory bowel disease (IBD), evolving from initial uncertainty regarding indication extrapolation and non-medical switching to widespread clinical acceptance. Early concerns focused mainly on the absence of disease-specific evidence and the potential impact of switching on effectiveness, safety, and immunogenicity. Over the past decade, however, extensive real-world evidence and randomized data have consistently supported the use of infliximab and adalimumab biosimilars in both biologic-naïve patients and patients switched from originator products. Recent systematic reviews and meta-analyses further reinforce these findings, showing preserved clinical remission, treatment persistence, inflammatory biomarkers, and immunogenicity after switching. The biosimilar landscape is now expanding to newer therapeutic targets, including ustekinumab, while biosimilar-to-biosimilar and multiple switching is becoming increasingly relevant in routine practice. Nevertheless, scientific interchangeability should not be equated to automatic substitution. Switching decisions should remain clinically supervised and involve gastroenterologists within a multidisciplinary framework, taking into account disease activity, previous response, safety, immunogenicity, and patient preferences. Appropriate communication is also essential to minimize a potential nocebo effect and to avoid unnecessary discontinuation. Biosimilars should therefore be considered fully established biological therapies rather than lower-tier alternatives to originator drugs. Future research should focus less on re-confirming single-switch equivalence and more on unresolved questions, including long-term outcomes after multiple switching, biosimilars of newer therapeutic targets, patient-reported outcomes, treatment persistence, and comparative pharmacoeconomic impact across healthcare systems.

PMID 42929266
阅读全文 →
PubMedCase reports in dermatology2026-10-25

A Rare Case Report of Dermal Mucinosis following Adalimumab Therapy for Psoriasis.

Asilian Ali A, Karimi Ghahderijani Farnaz F, Moradi Dastjerdi Soroosh S, Kashefi Zahra Z et al.

Cutaneous mucinoses are rare disorders defined by excessive dermal mucin deposition. Drug-induced cases are uncommon, and dermal mucinosis associated with adalimumab has rarely been reported. A 41-year-old woman presented with monomorphic, pruritic, skin-colored papules on the dorsal surfaces of both hands, which had first appeared 2 months earlier and had progressively worsened. She had a 10-year history of plaque psoriasis and had been receiving adalimumab therapy for the past year. With a primary diagnosis of dermatitis, treatment with a topical steroid was initiated, but the lack of improvement prompted a biopsy, which revealed mucinosis. The patient was diagnosed with papular mucinosis secondary to adalimumab therapy. Treatment with topical dimethyl sulfoxide resulted in partial improvement. This case underscores the rare occurrence of dermal mucinosis as a side effect of TNF-α inhibitors like adalimumab and highlights the importance of recognizing this potential adverse effect in patients on biologic therapies.

PMID 42923963
阅读全文 →
PubMedCase reports in gastroenterology2026-10-25

Aggregatibacter aphrophilus Bacteremia Associated with Systemic Hemangiomatosis in an Elderly Patient with Ulcerative Colitis: A Case Report.

Hendrie Abigail Grace AG, Pabby Vikas V

Older patients on biologic therapy for inflammatory bowel disease may be at increased risk for opportunistic infections, reflecting both age-related and immunosuppression-related factors. Aggregatibacter aphrophilus, a HACEK organism, is a rare cause of invasive infection that is typically associated with endovascular disease. We present the case of a 70-year-old male with ulcerative colitis treated with adalimumab who presented with 4 weeks of fevers, chills, night sweats, and weight loss. CT imaging revealed an intraluminal esophageal lesion and multiple hypodense splenic lesions. Endoscopy demonstrated a vascular-appearing esophageal lesion, and MRI revealed diffuse hemangiomatosis involving the esophagus, spleen, and head and neck musculature. Brain MRI demonstrated a lesion consistent with a septic embolus. Blood cultures grew A. aphrophilus. Applying the 2023 Duke-ISCVID criteria, this case fulfills criteria for possible infective endocarditis. The patient was treated with intravenous ceftriaxone for 4 weeks with clinical improvement. Adalimumab was held after discharge, and ulcerative colitis was subsequently managed with mesalamine with achievement of clinical remission. Clinicians should be vigilant for complications of immunosuppressive therapy for older patients with inflammatory bowel disease and maintain a broad differential for bacteremia, considering uncommon pathogens such as A. aphrophilus. The esophageal hemangioma precluding transesophageal echocardiography in this case illustrates the diagnostic importance of the 2023 Duke-ISCVID criteria and alternative cardiac imaging modalities in the evaluation of suspected native valve endocarditis when standard approaches are anatomically contraindicated.

PMID 42924077
阅读全文 →
PubMedCureus2026-10-25

Inflammatory Eye Disease and Immunosuppressive Therapy: A Rheumatologist's Perspective.

Aung Thanda T

Inflammatory eye disease, including uveitis, scleritis, episcleritis, peripheral ulcerative keratitis (PUK), and orbital inflammation, is among the most consequential extra-articular manifestations encountered by rheumatologists, both because ocular inflammation can cause irreversible vision loss within weeks and because it frequently signals an underlying systemic rheumatic disease. Ophthalmologists establish the anatomic diagnosis and assess the severity of intraocular inflammation; rheumatologists contribute systemic disease evaluation, selection of immunomodulatory therapy, and long-term toxicity monitoring. Neither specialty can optimally manage these patients alone. Systemic corticosteroids remain the fastest means of controlling acute ocular inflammation but are not a viable long-term strategy given their cumulative ocular and systemic toxicity. Methotrexate and mycophenolate mofetil are the best-supported conventional steroid-sparing agents, with comparable overall efficacy in randomized comparison, although subgroup data suggest that methotrexate may be preferred for posterior/panuveitis and mycophenolate for intermediate uveitis. Among biologics, adalimumab has the strongest randomized evidence for noninfectious intermediate, posterior, and panuveitis; infliximab and rituximab occupy important but more circumscribed, largely observational roles, particularly when ocular disease is associated with Behçet disease or antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Janus kinase (JAK) inhibitors are an emerging option for refractory disease, but the supporting evidence remains predominantly observational. This review synthesizes current evidence from recent guidelines, consensus recommendations, clinical trials, systematic reviews, and observational studies into a practical, phenotype-driven framework for the rheumatologist. It addresses which ocular presentations warrant urgent rheumatologic evaluation, which systemic diseases to consider, when to escalate beyond corticosteroids, how to select among conventional and targeted therapies, and how to structure ongoing multidisciplinary collaboration with ophthalmology.

PMID 42927373
阅读全文 →
PubMedAmerican journal of ophthalmology2026-10-23

Association Between Systemic TNF-α Inhibitor Use and Risk of Primary Open-Angle Glaucoma.

Hong Alexander T AT, Lin Forest F, Xu Benjamin Y BY, Weinreb Robert N RN

To evaluate the association between systemic tumor necrosis factor-alpha (TNF-α) inhibitor use and the long-term risk of primary open angle glaucoma (POAG), and to compare glaucoma risk among users of different TNF-α inhibitors. Retrospective, multicenter clinical cohort study. This retrospective, multicenter cohort study compared patients ≥40 years with and without TNF-α inhibitor use (2006-2026) using data from aggregated, de-identified electronic health records across 70 U.S. health care organizations. Patients prescribed TNF-α inhibitors (adalimumab, infliximab, etanercept, certolizumab pegol, or golimumab) were propensity matched (1:1) to controls without TNF-α inhibitor exposure based on demographics and systemic indications for TNF-a. Patients with a history of uveitis and related sequelae were excluded. New POAG diagnosis, identified by ICD-10 codes within 10 years of follow-up, was assessed using Cox proportional hazards models. Among 12,227 TNF-α inhibitor users and 1,354,651 controls, 11,915 matched pairs were analyzed (mean [SD] age 59 [10] years; 68% female). At 10 years, TNF-α inhibitor users were associated with a lower risk of POAG diagnosis compared to controls (2.0% vs. 3.3%; HR 0.70 [95% CI 0.59-0.82]; P<.001) In agent-specific analysis, adalimumab-users (n=4,962 per cohort) (HR 0.74 [0.57-0.96]) and infliximab users (n=2,134 per cohort; HR 0.68 [95% CI 0.47-0.97) were associated with a lower risk of POAG diagnosis compared to matched controls. No significant differences were observed in pairwise comparisons amongst TNF-α inhibitors. Systemic TNF-α inhibitor use, particularly adalimumab and infliximab, was associated with a modest but significant reduction in long-term POAG risk. These findings support a potential role of TNF-α-mediated inflammation in glaucomatous neurodegeneration.

PMID 42913929
阅读全文 →
PubMedThe Journal of the Association of Physicians of India2026-10-22

Reappraisal of Comparison of the Efficacy and Safety of Biosimilar Adalimumab with Innovator Adalimumab in Ankylosing Spondylitis.

Gawari Nitin Chintaman NC, Naik Tanvi T, Shingare Sujata Prakash SP, Hassan Yasir Y

PMID 42902677
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多adalimumab